Benefit was seen across all subgroups, including in patients with brain metastasis SAN ANTONIO – Adding tucatinib (Tukysa) to...
SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant...
More than 30 new drugs have been approved for pediatric cancer in the past 10 years, but progress has...
AI-powered, multilingual cancer research pipeline will accelerate the pace of global data curation and expand access to real-world clinical...
SAN ANTONIO – The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, will honor...
PHILADELPHIA – The American Association for Cancer Research (AACR) today congratulated Richard Pazdur, MD, on his appointment as Director...
PHILADELPHIA – The American Association for Cancer Research (AACR) today released a policy statement in support of a rule proposed...
PHILADELPHIA – Adding the investigational antibody ianalumab (VAY736) to ibrutinib (Imbruvica) allowed some patients with chronic lymphocytic leukemia (CLL)...
The small molecule KRAS inhibitor elironrasib targets the active GTP-bound form of KRAS G12C and led to encouraging responses...
BOSTON – FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), showed early signs...